Clinical TrialApr 22, 2026, 08:03 AM
Immutep's Efti Data Selected for ASCO 2026 Poster Presentation
AI Summary
Immutep Limited announced that an abstract detailing clinical and translational data for its lead product candidate, eftilagimod alfa (efti), has been selected for a poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data demonstrates that efti, an APC activator, induces rapid and sustained lymphocyte activation, which was associated with improved overall survival outcomes in patients with metastatic cancer across multiple late-stage studies. This presentation highlights the clinical relevance of efti's mechanism of action.
Key Highlights
- Abstract titled "Impact of eftilagimod alfa..." selected for poster presentation.
- Presentation at ASCO Annual Meeting from May 29 - June 2, 2026.
- Poster session on May 30, 2026, 1:30 PM-4:30 PM CDT.
- Data shows efti induces rapid, sustained lymphocyte activation.
- Immune activation markers linked to improved overall survival in metastatic cancer.
Price Impact
More from IMMP
More in Clinical Trial